Cover storyNPPA Slashes Cancer Drug Prices: ₹696 Becomes ₹73
India’s drug regulator capped mark-ups on 137 cancer drugs, and one brand falls by about 90% from November 9, 2026.
Cover storyIndia’s drug regulator capped mark-ups on 137 cancer drugs, and one brand falls by about 90% from November 9, 2026.

J&J's CAPLYTA meets primary YMRS endpoint in a second Phase 3 trial, clearing the clinical bar for an sNDA filing in bipolar I mania.

FDA's GFI #273 sets duration-of-use recommendations for veterinary antimicrobials, raising the compliance bar for animal drug sponsors.

ProQR reports full enrollment in AX-0811 Phase 1 cohorts and targets multiple clinical milestones through H1 2027, with €103M cash runway into mid-2028.

FibroBiologics reaches 170 issued patents covering fibroblast therapeutics and manufacturing methods, raising IP complexity for CDMOs entering the space.
Latest edition
SPONSORED
SPONSORED
SPONSORED
Nov 23
Nov 28From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Explore expert-led guides crafted for pharma professionals. Log in to download and stay ahead.








Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.

